Does cannabis use substitute for opioids? A preliminary exploratory survey in opioid maintenance patients

go back to reference Abrams DI, Couey P, Shade SB, Kelly M, Benowitz NL (2010) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90(6):844–841CrossRef Abrams DI, Couey P, Shade SB, Kelly M, Benowitz NL (2010) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90(6):844–841CrossRef

go back to reference Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Australian Institute of Health and Welfare (2002) 2001 national drug strategy household survey: first results. Curr Psychiatry Rep 61 Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Australian Institute of Health and Welfare (2002) 2001 national drug strategy household survey: first results. Curr Psychiatry Rep 61

go back to reference Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174(10):1668–1673CrossRefPubMedPubMedCentral Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174(10):1668–1673CrossRefPubMedPubMedCentral

go back to reference Betäubungsmittel-Verschreibungsverordnung vom 20. Januar 1998 (BGBl. I S. 74, 80), die zuletzt durch Artikel 2 der Verordnung vom 18. Mai 2021 (BGBl. I S. 1096) geändert worden ist, §5 Betäubungsmittel-Verschreibungsverordnung vom 20. Januar 1998 (BGBl. I S. 74, 80), die zuletzt durch Artikel 2 der Verordnung vom 18. Mai 2021 (BGBl. I S. 1096) geändert worden ist, §5

go back to reference Bushlin I, Rozenfeld R, Devi LA (2010) Cannabnoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10(1):80–86CrossRefPubMed Bushlin I, Rozenfeld R, Devi LA (2010) Cannabnoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10(1):80–86CrossRefPubMed

go back to reference Byrnes JJ, Johnson NL, Schenk ME, Byrnes EM (2012) Cannabinoid exposure in adolescent female rats induces transgenerational effects on morphine conditioned place preference in male offspring. J Psychopharmacol 26(10):1348–1354. https://doi.org/10.1177/0269881112443745. (Epub 2012 Apr 19)CrossRefPubMedPubMedCentral Byrnes JJ, Johnson NL, Schenk ME, Byrnes EM (2012) Cannabinoid exposure in adolescent female rats induces transgenerational effects on morphine conditioned place preference in male offspring. J Psychopharmacol 26(10):1348–1354. https://​doi.​org/​10.​1177/​0269881112443745​. (Epub 2012 Apr 19)CrossRefPubMedPubMedCentral

go back to reference Darke F (2007) National drug strategy. Dept. of Health and Aged Care, Canberra Darke F (2007) National drug strategy. Dept. of Health and Aged Care, Canberra

go back to reference Darke S, Duflou J, Kaye S (2007) Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. Addiction 102(11):1793–1797 (Epub 2007 Sep 3)CrossRefPubMed Darke S, Duflou J, Kaye S (2007) Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. Addiction 102(11):1793–1797 (Epub 2007 Sep 3)CrossRefPubMed

go back to reference Drogen- und Suchtbericht Oktober 2020 https://bit.ly/2vv2ZtB Drogen- und Suchtbericht Oktober 2020 https://​bit.​ly/​2vv2ZtB

go back to reference Dunn KE, Bergeria CL, Huhn AS, Speed TJ, Mun CJ, Vandrey R, Campbell CM (2021) Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology 46(8):1451–1459. https://doi.org/10.1038/s41386-021-01007-4. (Epub 2021 Apr 20)CrossRefPubMedPubMedCentral Dunn KE, Bergeria CL, Huhn AS, Speed TJ, Mun CJ, Vandrey R, Campbell CM (2021) Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology 46(8):1451–1459. https://​doi.​org/​10.​1038/​s41386-021-01007-4. (Epub 2021 Apr 20)CrossRefPubMedPubMedCentral

go back to reference Fergusson DM, Boden JM, Horwood LJ (2006) Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101(4):556–569CrossRefPubMed Fergusson DM, Boden JM, Horwood LJ (2006) Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101(4):556–569CrossRefPubMed

go back to reference Heidebrecht F, MacLeod MB, Dawkins L (2018) Predictors of heroin abstinence in opiate substitution therapy in heroin-omly users and dualusers of heroin and crack. Addict Behav 77:210–216CrossRefPubMed Heidebrecht F, MacLeod MB, Dawkins L (2018) Predictors of heroin abstinence in opiate substitution therapy in heroin-omly users and dualusers of heroin and crack. Addict Behav 77:210–216CrossRefPubMed

go back to reference Hursh SR, Galuska CM, Winger G, Woods JH (2005) The economics of drug abuse: a quantitative assassment of drug demand. Mol Interv 5(1):20–28CrossRefPubMed Hursh SR, Galuska CM, Winger G, Woods JH (2005) The economics of drug abuse: a quantitative assassment of drug demand. Mol Interv 5(1):20–28CrossRefPubMed

go back to reference Kvamme SL, Pedersen MM, Rømer Thomsen K, Thylstrup B (2021) Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample. Harm Reduct J 18(1):72. https://doi.org/10.1186/s12954-021-00520-5CrossRefPubMedPubMedCentral Kvamme SL, Pedersen MM, Rømer Thomsen K, Thylstrup B (2021) Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample. Harm Reduct J 18(1):72. https://​doi.​org/​10.​1186/​s12954-021-00520-5CrossRefPubMedPubMedCentral

go back to reference Li JX, Koek W, France CP (2012) Interactions between Δ (9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys. Behav Pharmacol 23(8):754–761CrossRefPubMedCentral Li JX, Koek W, France CP (2012) Interactions between Δ (9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys. Behav Pharmacol 23(8):754–761CrossRefPubMedCentral

go back to reference Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in delta (9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298(3):1007–1014PubMed Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in delta (9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298(3):1007–1014PubMed

go back to reference Lucas P, Reiman A, Earleywine M, McGowan SK, Oleson M, Coward MP, Thomas B (2013) Cannabis as a substitute for alcohol and other drugs: a dispensery-based survey of substitution effect in Canadian medical cannabis patients. Addiction Res Theory 21(5):435–442CrossRef Lucas P, Reiman A, Earleywine M, McGowan SK, Oleson M, Coward MP, Thomas B (2013) Cannabis as a substitute for alcohol and other drugs: a dispensery-based survey of substitution effect in Canadian medical cannabis patients. Addiction Res Theory 21(5):435–442CrossRef

go back to reference Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Isle L, Kay R, Capler R, Holtzman S (2016) Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug and Alcohol Rev 35(3):326–333CrossRef Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Isle L, Kay R, Capler R, Holtzman S (2016) Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug and Alcohol Rev 35(3):326–333CrossRef

go back to reference MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S (2021) Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain. Front Pharmacol 12:633168. https://doi.org/10.3389/fphar.2021.633168CrossRefPubMedPubMedCentral MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S (2021) Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain. Front Pharmacol 12:633168. https://​doi.​org/​10.​3389/​fphar.​2021.​633168CrossRefPubMedPubMedCentral

go back to reference Maguire DR, France CP (2018) Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio. Eur J Pharmacol 819:217–224. https://doi.org/10.1016/j.ejphar.2017.11.038. (Epub 2017 Nov 26)CrossRefPubMed Maguire DR, France CP (2018) Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio. Eur J Pharmacol 819:217–224. https://​doi.​org/​10.​1016/​j.​ejphar.​2017.​11.​038. (Epub 2017 Nov 26)CrossRefPubMed

go back to reference Maguire DR, Yang W, France CP (2013) Interactions between µ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination and drug self-administration. J Pharmacol Exp Ther 345(3):354–362CrossRefPubMedPubMedCentral Maguire DR, Yang W, France CP (2013) Interactions between µ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination and drug self-administration. J Pharmacol Exp Ther 345(3):354–362CrossRefPubMedPubMedCentral

go back to reference Maguire DR, Yang W, France CP (2016) Interactions of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Behav Pharmacol 27(2–3 Spec Issue):249–257CrossRefPubMedPubMedCentral Maguire DR, Yang W, France CP (2016) Interactions of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Behav Pharmacol 27(2–3 Spec Issue):249–257CrossRefPubMedPubMedCentral

go back to reference McGinty EE, Tormohlen KN, Seewald NJ, Bicket MC, McCourt AD, Rutkow L, White SA, Stuart EA (2023) Effects of U.S. State medical cannabis laws on treatment of chronic noncancer pain. Ann Internal Med 176(7):904–912. https://doi.org/10.7326/M23-0053CrossRef McGinty EE, Tormohlen KN, Seewald NJ, Bicket MC, McCourt AD, Rutkow L, White SA, Stuart EA (2023) Effects of U.S. State medical cannabis laws on treatment of chronic noncancer pain. Ann Internal Med 176(7):904–912. https://​doi.​org/​10.​7326/​M23-0053CrossRef

go back to reference Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, Mullany E, Lee A, Khan AR, Ahmadi R, Ferrari AJ, Kasaeian A, Werdecker A, Carter A, Zipkin B, Sartorius B, Serdar B, Sykes BL, Troeger C, Fitzmaurice C, Rehm CD, Santomauro D, Kim D, Colombara D, Schwebel DC, Tsoi D, Kolte D, Nsoesie E, Nichols E, Oren E, Charlson FJ, Patton CG, Roth GA, Hosgood HD, Whitford HA, Kyu H, Erskine HE, Huang H, Martopullo I, Singh JA, Nachega JB, Sanabria JR, Abbas K, Ong K, Tabb K, Krohn KJ, Cornaby L, Degenhardt L, Moses M, Farvid M, Griswold M, Criqui M, Bell M, Nguyen M, Wallin M, Mirarefin M, Qorbani M, Younis M, Fullman N, Liu P, Briant P, Fona P, Havmollet R, Leung R, Kimokoti R, Bazargan-Hejazi S, Hay SI, Yadgir S, Birjyukov S, Vollset SE, Alam T, Frank T, Farid T, Miller T, Vos T, Bärnihausen T, Gebrehlwot TT, Yano Y, Al-Aly Z, Mehari A, Handal A, Kandel A, Anderson B, Biroscak B, Mozaffarian D, Dorsey ER, Ding EL, Park EK, Wagner G, Hu G, Chen H, Sunshine JE, Khubchandani J, Leasher J, Leung J, Salomon JE, Unutzer J, Cahil L, Cooper L, Horino M, Brauer M, Breitborde N, Hotez P, Topor-Madry R, Soneji S, Stranges S, James S, Amrock S, Jayaraman S, Patel T, Akinyemiju T, Skirbekk V, Kinfu Y, Bhutta JB, Murray CJL (2018) The state of US health, 1999–2016: burden of diseases, injuries and risk factors among Us states. JAMA 319(14):1444–1472. https://doi.org/10.1001/jama.2018.0158. (Published online 2018 Apr 10)CrossRefPubMedPubMedCentral Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, Mullany E, Lee A, Khan AR, Ahmadi R, Ferrari AJ, Kasaeian A, Werdecker A, Carter A, Zipkin B, Sartorius B, Serdar B, Sykes BL, Troeger C, Fitzmaurice C, Rehm CD, Santomauro D, Kim D, Colombara D, Schwebel DC, Tsoi D, Kolte D, Nsoesie E, Nichols E, Oren E, Charlson FJ, Patton CG, Roth GA, Hosgood HD, Whitford HA, Kyu H, Erskine HE, Huang H, Martopullo I, Singh JA, Nachega JB, Sanabria JR, Abbas K, Ong K, Tabb K, Krohn KJ, Cornaby L, Degenhardt L, Moses M, Farvid M, Griswold M, Criqui M, Bell M, Nguyen M, Wallin M, Mirarefin M, Qorbani M, Younis M, Fullman N, Liu P, Briant P, Fona P, Havmollet R, Leung R, Kimokoti R, Bazargan-Hejazi S, Hay SI, Yadgir S, Birjyukov S, Vollset SE, Alam T, Frank T, Farid T, Miller T, Vos T, Bärnihausen T, Gebrehlwot TT, Yano Y, Al-Aly Z, Mehari A, Handal A, Kandel A, Anderson B, Biroscak B, Mozaffarian D, Dorsey ER, Ding EL, Park EK, Wagner G, Hu G, Chen H, Sunshine JE, Khubchandani J, Leasher J, Leung J, Salomon JE, Unutzer J, Cahil L, Cooper L, Horino M, Brauer M, Breitborde N, Hotez P, Topor-Madry R, Soneji S, Stranges S, James S, Amrock S, Jayaraman S, Patel T, Akinyemiju T, Skirbekk V, Kinfu Y, Bhutta JB, Murray CJL (2018) The state of US health, 1999–2016: burden of diseases, injuries and risk factors among Us states. JAMA 319(14):1444–1472. https://​doi.​org/​10.​1001/​jama.​2018.​0158. (Published online 2018 Apr 10)CrossRefPubMedPubMedCentral

go back to reference Morel LJ, Giros B, Daugé V (2009) Adolescent exposure to chronic delt-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology 34(11):2469–2476CrossRefPubMed Morel LJ, Giros B, Daugé V (2009) Adolescent exposure to chronic delt-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology 34(11):2469–2476CrossRefPubMed

go back to reference National Institute on Drug Abuse (2018) Opioid overdoses by state. National Institutes of Health. https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/california-opioid-involved-deaths-related-harms National Institute on Drug Abuse (2018) Opioid overdoses by state. National Institutes of Health. https://​www.​drugabuse.​gov/​drug-topics/​opioids/​opioid-summaries-by-state/​california-opioid-involved-deaths-related-harms

go back to reference Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, Koob GF, de Fonseca FR (2001) functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 21(14):5344–5350CrossRefPubMedPubMedCentral Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, Koob GF, de Fonseca FR (2001) functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 21(14):5344–5350CrossRefPubMedPubMedCentral

go back to reference Navarro M, Chowen J, Carrera MRA, del Arco I, Villanúa MA, Martin Y, Roberts AJ, Koob GF, de Fonseca FR (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. NeuroReport 9(15):3397–3402CrossRefPubMed Navarro M, Chowen J, Carrera MRA, del Arco I, Villanúa MA, Martin Y, Roberts AJ, Koob GF, de Fonseca FR (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. NeuroReport 9(15):3397–3402CrossRefPubMed

go back to reference Reiman A (2009) Cannabis as a substitute for alcohol and other drugs. Harm Reduct J 2009(6):35CrossRef Reiman A (2009) Cannabis as a substitute for alcohol and other drugs. Harm Reduct J 2009(6):35CrossRef

go back to reference Salio C, Fischer J, Franzoni MF, Mackie K, Taneko T, Conrath M (2001) CB-1 Cannabinid and µ-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. NeuroReport 12(17):3689–3692CrossRefPubMed Salio C, Fischer J, Franzoni MF, Mackie K, Taneko T, Conrath M (2001) CB-1 Cannabinid and µ-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. NeuroReport 12(17):3689–3692CrossRefPubMed

go back to reference Scavone JL, Sterling RC, Van Bockstale EJ (2013) Cannabinoid and opiod interactions: implications for opiate dependence and withdrawal. Neuroscience 248(17):637–654CrossRefPubMed Scavone JL, Sterling RC, Van Bockstale EJ (2013) Cannabinoid and opiod interactions: implications for opiate dependence and withdrawal. Neuroscience 248(17):637–654CrossRefPubMed

go back to reference Segura LE, Mauro CM, Levy NS, Khauli N, Philbin MM, Mauro OM, Martins SS (2019) Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Netw Open 2(7):e197216. https://doi.org/10.1001/jamanetworkopen.2019.7216CrossRefPubMedPubMedCentral Segura LE, Mauro CM, Levy NS, Khauli N, Philbin MM, Mauro OM, Martins SS (2019) Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Netw Open 2(7):e197216. https://​doi.​org/​10.​1001/​jamanetworkopen.​2019.​7216CrossRefPubMedPubMedCentral

go back to reference Skopp G, Strohbeck-Kuehner P, Mann K, Hermann D (2007) Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int 170(1):46–50CrossRefPubMed Skopp G, Strohbeck-Kuehner P, Mann K, Hermann D (2007) Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int 170(1):46–50CrossRefPubMed

go back to reference Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG (2020) Positive allosteric modulation of CB1-cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward. Front Mol Neurosci. 13:54. https://doi.org/10.3389/fnmol.2020.00054CrossRefPubMedPubMedCentral Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG (2020) Positive allosteric modulation of CB1-cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward. Front Mol Neurosci. 13:54. https://​doi.​org/​10.​3389/​fnmol.​2020.​00054CrossRefPubMedPubMedCentral

go back to reference Takakuwa KM, Sulak D (2020) A survey on the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronic pain at three medical cannabis practice sites. Cureus 12(12):e11848. https://doi.org/10.7759/cureus.11848CrossRefPubMedPubMedCentral Takakuwa KM, Sulak D (2020) A survey on the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronic pain at three medical cannabis practice sites. Cureus 12(12):e11848. https://​doi.​org/​10.​7759/​cureus.​11848CrossRefPubMedPubMedCentral

go back to reference Viganò D, Rubino T, Parolaro D (2005) Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Bichem Behav 81(2):360–368CrossRef Viganò D, Rubino T, Parolaro D (2005) Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Bichem Behav 81(2):360–368CrossRef

go back to reference Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO (2017) Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev 51:15–29. https://doi.org/10.1016/j.cpr.2016.10.002CrossRefPubMed Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO (2017) Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev 51:15–29. https://​doi.​org/​10.​1016/​j.​cpr.​2016.​10.​002CrossRefPubMed

go back to reference Wen H, Hockenberry JM (2028) Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees. JAMA Intern Med 178(5):673–679. https://doi.org/10.1001/jamainternmed.2018.1007CrossRef Wen H, Hockenberry JM (2028) Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees. JAMA Intern Med 178(5):673–679. https://​doi.​org/​10.​1001/​jamainternmed.​2018.​1007CrossRef

go back to reference Yamaguchi T, Hagiwara T, Tanaka H, Sugiura S, Waku K, Shoyama Y, Watanabe S, Yamamoto T (2001) Endogenous cannabinoid, 2-arachidonoylglygerol, attenuaes naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909(1–2):121–126CrossRefPubMed Yamaguchi T, Hagiwara T, Tanaka H, Sugiura S, Waku K, Shoyama Y, Watanabe S, Yamamoto T (2001) Endogenous cannabinoid, 2-arachidonoylglygerol, attenuaes naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909(1–2):121–126CrossRefPubMed

go back to reference Zhang H, Lipinski AA, Liktor-Busa E, Smith AF, Moutal A, Khanna R, Langlais PR, Largent-Milnes TM, Vanderah TW (2021) The effects of repeated morphine treatment on the endogenous cannabinoid system in the ventral tegmental area. Front Pharmacol 12:632757. https://doi.org/10.3389/fphar.2021.632757CrossRefPubMedPubMedCentral Zhang H, Lipinski AA, Liktor-Busa E, Smith AF, Moutal A, Khanna R, Langlais PR, Largent-Milnes TM, Vanderah TW (2021) The effects of repeated morphine treatment on the endogenous cannabinoid system in the ventral tegmental area. Front Pharmacol 12:632757. https://​doi.​org/​10.​3389/​fphar.​2021.​632757CrossRefPubMedPubMedCentral